Price information




Scheduled Reports

Interim Report Q3

About company

PHI leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

  • CEO Peter Egelberg
  • Chairm. of the Board Klas Cramborn

Instrument Information

  • Full Name
  • Short Name
  • No of shares
  • ISIN code
  • OrderBookID
  • CFI (ISO 10962)
  • FISN (ISO 18774)
  • Par Value kr
  • First Traded
  • Type